LUMOSA THERAPEUTICS CO LTD (6535) AI Stock Analysis

LUMOSA THERAPEUTICS CO LTD

(TPEx:6535)

Select Model

Rating:37Underperform

Price Target:TWD 66.00▼(-18.32% Downside)

Action:initiatedcoverage

Date:11/10/26

The overall score is at the minimum of 37, reflecting severe and broad-based weakness. The most significant factor is the company's rapidly deteriorating financial health, marked by massive and accelerating cash burn that is consuming its strong balance sheet. This is compounded by a persistently bearish technical trend, with the stock trading deep below all key moving averages, and a negative P/E ratio that underscores the lack of profitability. The company's only strength, its debt-free balance sheet, is being actively undermined by its operations, leaving no positive catalysts to offset the overwhelming risks.

Positive Factors

Very low leverageThe extremely low debt burden gives Lumosa meaningful financial flexibility relative to a highly leveraged biotech. It reduces balance-sheet pressure and leaves more room to fund clinical development, pursue partnerships, or absorb operating volatility while management works toward commercialization.

Negative Factors

Severe persistent lossesThe depth and persistence of operating losses show that Lumosa has not yet demonstrated a stable earnings model. Continued losses can consume resources needed for clinical development, make profitability dependent on future milestones, and increase the importance of successful commercialization or partnering outcomes.

LUMOSA THERAPEUTICS CO LTD (6535) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 13.04B
Dividend Yield: ―
Average Volume (3M): 280.95K
Price to Earnings (P/E): -33.7
Beta (1Y): 0.21
Revenue Growth: -24.84%
EPS Growth: 9.09%
Country: TW
Employees: 36
Sector: General
Sector Strength: 55
Industry: Biotechnology

LUMOSA THERAPEUTICS CO LTD Business Overview & Revenue Model

Company Description

Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has...

LUMOSA THERAPEUTICS CO LTD Financial Statement Overview

Summary

Financial performance is critically weak. The income statement shows a 15.9% revenue decline and a massive $346.6M net loss. Cash flow is even worse, with a -$357.1M free cash flow burn accelerating by 14.8% YoY. The only mitigating factor is a strong balance sheet with $1.51B in equity and negligible debt, but this is being rapidly eroded by unsustainable losses.

Income Statement

18Very Negative

Balance Sheet

72Positive

Cash Flow

15Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	34.37M	35.83M	39.15M	56.92M	26.64M	17.36M
Gross Profit	18.25M	21.87M	17.71M	41.48M	14.56M	9.89M
EBITDA	-254.62M	-322.23M	-428.24M	-226.68M	-482.13M	128.31M
Net Income	-370.06M	-346.62M	-424.78M	-238.04M	-494.66M	95.95M
Balance Sheet
Total Assets	1.37B	1.65B	2.13B	1.66B	1.89B	2.35B
Cash, Cash Equivalents and Short-Term Investments	633.00M	798.34M	1.35B	844.31M	1.18B	1.45B
Total Debt	3.48M	6.92M	8.48M	12.61M	4.69M	11.49M
Total Liabilities	123.58M	131.04M	205.46M	227.69M	215.72M	230.11M
Stockholders Equity	1.24B	1.51B	1.91B	1.40B	1.63B	2.12B
Cash Flow
Free Cash Flow	-257.63M	-357.07M	-296.78M	-343.23M	-302.74M	-453.18M
Operating Cash Flow	-257.63M	-356.41M	-296.33M	-328.21M	-300.46M	-452.60M
Investing Cash Flow	249.88M	366.10M	-787.10M	240.58M	-69.20M	-36.98M
Financing Cash Flow	-6.85M	-63.59M	893.62M	-3.94M	46.17M	431.28M

LUMOSA THERAPEUTICS CO LTD Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6535 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6576	42Neutral	TWD 11.52B	519.28	―	―	6.41%	―
TW:6617	40Underperform	TWD 15.11B	-92.22	―	―	11.66%	-72.96%
TW:6945	40Underperform	TWD 11.22B	-21.76	―	―	―	―
TW:6535	37Underperform	TWD 12.33B	-33.67	―	―	-24.84%	9.09%

* General Sector Average

Performance Comparison

TW:6535 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6535	LUMOSA THERAPEUTICS CO LTD	80.80	-108.20	-57.25%
TW:6467	TAHO Pharmaceuticals Ltd	230.00	61.50	36.50%
TW:6576	Foresee Pharmaceuticals Co., Ltd.	73.00	-12.20	-14.32%
TW:6617	Gongwin Biopharm Holdings Co., Ltd.	126.50	41.90	49.53%
TW:6748	ACRO Biomedical Co., Ltd.	169.50	111.12	190.35%
TW:6945	AP Biosciences, Inc.	117.50	7.00	6.33%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

LUMOSA THERAPEUTICS CO LTD AI Stock Analysis